CytoAgents Inc. completed the dose-limiting toxicity observation for the first cohort in a trial targeting CRS in blood cancer patients. The Safety Review Committee approved dose escalation for the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results